Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Medication Slows Progression of Myopia in Children

26.08.2008
Daily treatment with a medication called pirenzepine can slow the rate of progressive myopia, or nearsightedness, in children, reports a study in the August issue of the Journal of AAPOS (American Association for Pediatric Ophthalmology and Strabismus).

Led by Dr. R. Michael Stiatkowski of Dean McGee Eye Institute/University of Oklahoma Department of Ophthalmology, the researchers evaluated the effects of pirenzepine in children with myopia. Myopia—sometimes called nearsightedness—is a condition in which focus on near objects is good, but distant objects appear blurry. Caused by a problem with the length of the eyeball or the curvature of the cornea, myopia gets worse over time in many children.

In the study, children with myopia were randomly assigned to treatment with pirenzepine gel or an inactive placebo gel. After a year of treatment, the average increase in myopia was significantly less for children using pirenzepine. The new study presents the final results in 84 patients who continued treatment for a total of two years: 53 with pirenzepine and 31 with placebo.

Although myopia worsened in both groups of children, the rate of progression was slower with pirenzepine. At the end of two years, myopia increased by an average of 0.58 diopters in children using pirenzepine versus 0.99 diopters with placebo. (All children initially had "moderate" myopia, with an average refractive error of about -2.00 diopters.)

New glasses are generally prescribed when myopia worsens by at least 0.75 diopters. During the study, 37 percent of children using pirenzepine met this cut-off point compared with 68 percent of the placebo group. With glasses, all children had about 20/20 vision at both the beginning and end of the study.

Pirenzepine treatment was generally safe, although eleven percent of children stopped using it because of side effects such as eye irritation. The drug also caused mild dilation of the pupils. The amount of change in the length of the eyeball was not significantly different between groups, although more research is needed to determine whether pirenzepine affects the growth of the eyes.

Myopia is the leading cause of loss of vision worldwide, affecting at least 25 percent of U.S. adults. Effective treatments to prevent or delay progressive myopia may reduce the risk of serious complications such as detached retina and glaucoma—even for children with moderate myopia, the risk of retinal detachment is increased by up to four times.

Treatments to slow worsening myopia could also have important quality-of-life benefits. For example, while children with -1.00 diopter of myopia may need glasses only part-time, those with -2.00 diopters will probably need glasses for all activities, including school and sports.

Previous studies have suggested that a drug called atropine can delay progression of myopia. The new results show that pirenzepine—a related drug with fewer side effects—is also safe and effective for this purpose.

More research will be needed before pirenzepine can be widely recommended for children with myopia. Key questions include the long-term effects and optimal length of pirenzepine treatment. In addition, more convenient and practical methods of drug administration may help to overcome some of the disadvantages of pirenzepine gel.

Jayne Dawkins | alfa
Further information:
http://www.elsevier.com

Further reports about: Myopia Strabismus eyeball nearsightedness pirenzepine progressive myopia

More articles from Health and Medicine:

nachricht New malaria analysis method reveals disease severity in minutes
14.08.2017 | University of British Columbia

nachricht New type of blood cells work as indicators of autoimmunity
14.08.2017 | Instituto de Medicina Molecular

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Fizzy soda water could be key to clean manufacture of flat wonder material: Graphene

Whether you call it effervescent, fizzy, or sparkling, carbonated water is making a comeback as a beverage. Aside from quenching thirst, researchers at the University of Illinois at Urbana-Champaign have discovered a new use for these "bubbly" concoctions that will have major impact on the manufacturer of the world's thinnest, flattest, and one most useful materials -- graphene.

As graphene's popularity grows as an advanced "wonder" material, the speed and quality at which it can be manufactured will be paramount. With that in mind,...

Im Focus: Exotic quantum states made from light: Physicists create optical “wells” for a super-photon

Physicists at the University of Bonn have managed to create optical hollows and more complex patterns into which the light of a Bose-Einstein condensate flows. The creation of such highly low-loss structures for light is a prerequisite for complex light circuits, such as for quantum information processing for a new generation of computers. The researchers are now presenting their results in the journal Nature Photonics.

Light particles (photons) occur as tiny, indivisible portions. Many thousands of these light portions can be merged to form a single super-photon if they are...

Im Focus: Circular RNA linked to brain function

For the first time, scientists have shown that circular RNA is linked to brain function. When a RNA molecule called Cdr1as was deleted from the genome of mice, the animals had problems filtering out unnecessary information – like patients suffering from neuropsychiatric disorders.

While hundreds of circular RNAs (circRNAs) are abundant in mammalian brains, one big question has remained unanswered: What are they actually good for? In the...

Im Focus: RAVAN CubeSat measures Earth's outgoing energy

An experimental small satellite has successfully collected and delivered data on a key measurement for predicting changes in Earth's climate.

The Radiometer Assessment using Vertically Aligned Nanotubes (RAVAN) CubeSat was launched into low-Earth orbit on Nov. 11, 2016, in order to test new...

Im Focus: Scientists shine new light on the “other high temperature superconductor”

A study led by scientists of the Max Planck Institute for the Structure and Dynamics of Matter (MPSD) at the Center for Free-Electron Laser Science in Hamburg presents evidence of the coexistence of superconductivity and “charge-density-waves” in compounds of the poorly-studied family of bismuthates. This observation opens up new perspectives for a deeper understanding of the phenomenon of high-temperature superconductivity, a topic which is at the core of condensed matter research since more than 30 years. The paper by Nicoletti et al has been published in the PNAS.

Since the beginning of the 20th century, superconductivity had been observed in some metals at temperatures only a few degrees above the absolute zero (minus...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Call for Papers – ICNFT 2018, 5th International Conference on New Forming Technology

16.08.2017 | Event News

Sustainability is the business model of tomorrow

04.08.2017 | Event News

Clash of Realities 2017: Registration now open. International Conference at TH Köln

26.07.2017 | Event News

 
Latest News

Gold shines through properties of nano biosensors

17.08.2017 | Physics and Astronomy

Greenland ice flow likely to speed up: New data assert glaciers move over sediment, which gets more slippery as it gets wetter

17.08.2017 | Earth Sciences

Mars 2020 mission to use smart methods to seek signs of past life

17.08.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>